191 related articles for article (PubMed ID: 20166183)
21. Increased number of CD16(+)CD56(dim) NK cells in peripheral blood mononuclear cells after allogeneic cord blood transplantation.
Tanaka J; Sugita J; Asanuma S; Arita K; Shono Y; Kikutchi M; Shiratori S; Wakasa K; Yasumoto A; Shigematu A; Kondo T; Kobayashi T; Asaka M; Imamura M
Hum Immunol; 2009 Sep; 70(9):701-5. PubMed ID: 19524005
[TBL] [Abstract][Full Text] [Related]
22. CD8+ NK cells are predominant in chimpanzees, characterized by high NCR expression and cytokine production, and preserved in chronic HIV-1 infection.
Rutjens E; Mazza S; Biassoni R; Koopman G; Ugolotti E; Fogli M; Dubbes R; Costa P; Mingari MC; Greenwood EJ; Moretta L; De Maria A; Heeney JL
Eur J Immunol; 2010 May; 40(5):1440-50. PubMed ID: 20306468
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK
Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
[TBL] [Abstract][Full Text] [Related]
24. Natural killer cell subpopulations in putative resistant individuals and patients with active Mycobacterium tuberculosis infection.
Barcelos W; Sathler-Avelar R; Martins-Filho OA; Carvalho BN; Guimarães TM; Miranda SS; Andrade HM; Oliveira MH; Toledo VP
Scand J Immunol; 2008 Jul; 68(1):92-102. PubMed ID: 18484953
[TBL] [Abstract][Full Text] [Related]
25. CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation.
Béziat V; Duffy D; Quoc SN; Le Garff-Tavernier M; Decocq J; Combadière B; Debré P; Vieillard V
J Immunol; 2011 Jun; 186(12):6753-61. PubMed ID: 21555534
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal analysis of peripheral and intrahepatic NK cells in chronic HCV patients during antiviral therapy.
Spaan M; van Oord GW; Janssen HL; de Knegt RJ; Boonstra A
Antiviral Res; 2015 Nov; 123():86-92. PubMed ID: 26363298
[TBL] [Abstract][Full Text] [Related]
27. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells.
Takahashi E; Kuranaga N; Satoh K; Habu Y; Shinomiya N; Asano T; Seki S; Hayakawa M
Scand J Immunol; 2007 Feb; 65(2):126-38. PubMed ID: 17257217
[TBL] [Abstract][Full Text] [Related]
28. Murine CXCR3+CD27bright NK cells resemble the human CD56bright NK-cell population.
Marquardt N; Wilk E; Pokoyski C; Schmidt RE; Jacobs R
Eur J Immunol; 2010 May; 40(5):1428-39. PubMed ID: 20186880
[TBL] [Abstract][Full Text] [Related]
29. Changes in NK cell counts and receptor expressions and emergence of CD3(dim)/CD56+ cells in HIV-1 infected patients in China.
Fu GF; Hao S; Zhao JL; Xu XQ; Guo HX; Hu HY; Yang HT; Li L; Xu JS; Qiu T; Huan XP; Hou YY
Viral Immunol; 2009 Apr; 22(2):105-16. PubMed ID: 19326997
[TBL] [Abstract][Full Text] [Related]
30. Downregulation and altered function of natural killer cells in hepatitis B virus patients treated with entecavir.
Zhao PW; Jia FY; Shan YX; Ji HF; Feng JY; Niu JQ; Ayana DA; Jiang YF
Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):190-6. PubMed ID: 23278368
[TBL] [Abstract][Full Text] [Related]
31. Natural killer cell lytic activity and CD56(dim) and CD56(bright) cell distributions during and after intensive training.
Suzui M; Kawai T; Kimura H; Takeda K; Yagita H; Okumura K; Shek PN; Shephard RJ
J Appl Physiol (1985); 2004 Jun; 96(6):2167-73. PubMed ID: 14752119
[TBL] [Abstract][Full Text] [Related]
32. Genetically associated CD16(+)56(-) natural killer cell interferon (IFN)-αR expression regulates signaling and is implicated in IFN-α-induced hepatitis C virus decline.
Conry SJ; Meng Q; Hardy G; Yonkers NL; Sugalski JM; Hirsch A; Davitkov P; Compan A; Falck-Ytter Y; Blanton RE; Rodriguez B; Harding CV; Anthony DD
J Infect Dis; 2012 Apr; 205(7):1131-41. PubMed ID: 22351942
[TBL] [Abstract][Full Text] [Related]
33. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
35. High-dose interferon-alpha 2b plus ribavirin combination therapy for GB virus-C/hepatitis G virus infection--a study in patients with chronic hepatitis C.
Cheng PN; Jen CM; Young KC; Chen CY; Lu SN; Wang CS; Chang TT
Hepatogastroenterology; 2003; 50(50):449-52. PubMed ID: 12749244
[TBL] [Abstract][Full Text] [Related]
36. Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment.
Bozzano F; Picciotto A; Costa P; Marras F; Fazio V; Hirsch I; Olive D; Moretta L; De Maria A
Eur J Immunol; 2011 Oct; 41(10):2905-14. PubMed ID: 21695691
[TBL] [Abstract][Full Text] [Related]
37. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
38. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection.
Oliviero B; Mele D; Degasperi E; Aghemo A; Cremonesi E; Rumi MG; Tinelli C; Varchetta S; Mantovani S; Colombo M; Mondelli MU
J Hepatol; 2013 Jul; 59(1):38-44. PubMed ID: 23499727
[TBL] [Abstract][Full Text] [Related]
39. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells.
Gaddy J; Broxmeyer HE
Cell Immunol; 1997 Sep; 180(2):132-42. PubMed ID: 9341743
[TBL] [Abstract][Full Text] [Related]
40. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B.
Tjwa ET; van Oord GW; Hegmans JP; Janssen HL; Woltman AM
J Hepatol; 2011 Feb; 54(2):209-18. PubMed ID: 21095036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
